Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Here is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy?
Exact Sciences (EXAS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EXAS crossed above the 20-day moving average, suggesting a short-term bullish trend.
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.
Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)
Exact Sciences Corporation (NASDAQ:EXAS ) Baird 2025 Global Healthcare Conference September 9, 2025 10:50 AM EDT Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Financial Officer Raj Pudipeddi - EVP, Chief Growth Officer Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior Research Analyst [Audio Gap] diagnostics here at Baird.
Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Good afternoon.
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Derek Leckow - Vice President of Investor Relations Kevin T. Conroy - Chairman of the Board & CEO Conference Call Participants Andrew Frederick Brackmann - William Blair & Company L.L.C.
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates
Exact Sciences (EXAS) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.09 per share a year ago.
